Search the Studies

63 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
19-C-0016Natural History and Biospecimen Acquisition Study for Children and Adults with Rare Solid TumorsParticipants currently recruited/enrolled0-125 YearsNCI Peripheral Osteosarcoma
000908-DKPeripheral Blood and Urine Immune Cell Phenotyping in Membranous Nephropathy using FACS and Single Cell RNA-seqParticipants currently recruited/enrolled18-125 YearsNIDDKPeripheral
000633-CPhase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid MalignanciesParticipants currently recruited/enrolled18-125 YearsNCI Peripheral
000625-NInvestigational use of Neuromuscular UltrasoundParticipants currently recruited/enrolled18-125 YearsNINDSPeripheral
000613-CPhase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood StParticipants currently recruited/enrolled12-125 YearsNCI Peripheral
000473-CA Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic CholangiocarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Peripheral
000317-CA Phase II, Open-Label Trial of PT-112 in Subjects with Thymoma and Thymic CarcinomaParticipants currently recruited/enrolled18-125 YearsNCI Peripheral
21-C-0032GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor ExposureParticipants currently recruited/enrolled0-35 YearsNCI Osteosarcoma
21-C-0021SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) ImagingParticipants currently recruited/enrolled6-125 YearsNCI Osteosarcoma
21-C-0015Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or GliosarcomaParticipants currently recruited/enrolled18-125 YearsNCI Peripheral
20-M-0157PET Imaging of Cyclooxygenase in Participants with Major Depressive Disorder (MDD)Participants currently recruited/enrolled18-70 YearsNIMH Peripheral
20-H-0137A Study to Evaluate the Effects of Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects with Stable Sickle Cell DiseaseCompleted Study; data analyses ongoing18-46 YearsNHLBIPeripheral
20-C-0127A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignanciesParticipants currently recruited/enrolled18-125 YearsNCI Peripheral
20-C-0121Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelParticipants currently recruited/enrolled18-125 YearsNCI Peripheral
20-C-0041Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic InjuriesEnrolling by Invitation1-125 YearsNCI Peripheral
20-C-0023First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid TumorsParticipants currently recruited/enrolled12-125 YearsNCI Peripheral
19-I-0080Haploidentical Transplant for Patients with Chronic Granulomatous Disease (CGD) using Alemtuzumab, Busulfan and TBI with Post-Transplant CyclophosphamideParticipants currently recruited/enrolled4-65 YearsNIAIDPeripheral
19-H-0118Repeat Peripheral Blood Stem Cell Transplantation for Patients with Sickle Cell Disease or Beta-Thalassemia and Falling Donor Myeloid Chimerism LevelsParticipants currently recruited/enrolled2-80 YearsNHLBIPeripheral
19-C-0134A Phase 1/1b Study of Enhancement of Immune Reconstitution and Vaccine Responses with Administration of Recombinant Human IL-7-hyFc (NT-I7) in Older Subjects Following ChemotherapyParticipants currently recruited/enrolled60-125 YearsNCI Peripheral
19-C-0085Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell LymphomaClinical hold/Recruitment or enrollment suspended12-125 YearsNCI Peripheral
19-C-0076A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell MalignanciesCompleted Study; data analyses ongoing18-125 YearsNCI Peripheral
19-C-0061A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination with the mTOR Inhibitor Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath TumorsParticipants currently recruited/enrolled12-125 YearsNCI Peripheral
19-C-0017A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsParticipants currently recruited/enrolled18-70 YearsNCI Peripheral
18-H-0090Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH using Peripheral Blood Stem Cells and post-transplant Cyclophosphamide for GVHD prophylaxisParticipants currently recruited/enrolled4-75 YearsNHLBIPeripheral
17-H-0124Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using PlerixaforCompleted Study; data analyses ongoing18-125 YearsNHLBIPeripheral
17-H-0069Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell DiseaseParticipants currently recruited/enrolled2-125 YearsNHLBIPeripheral
17-C-0113A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsParticipants currently recruited/enrolled18-70 YearsNCI Peripheral
17-C-0048Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell LymphomasCompleted Study; data analyses ongoing18-73 YearsNCI Peripheral
16-I-0032High Dose Peripheral Blood Stem Cell Transplantation with Post Transplant Cyclophosphamide for Patients with Chronic Granulomatous DiseaseNo longer recruiting/follow-up only4-65 YearsNIAIDPeripheral
16-C-0138Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell TherapyParticipants currently recruited/enrolled18-99 YearsNCI Peripheral
16-C-0135A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)No longer recruiting/follow-up only18-125 YearsNCI Peripheral
16-C-0131A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to Patients with CD70-Expressing CancersParticipants currently recruited/enrolled18-70 YearsNCI Peripheral
16-C-0062A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)Completed Study; data analyses ongoing18-125 YearsNCI Peripheral
15-H-0016A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.No longer recruiting/follow-up only18-125 YearsNHLBIPeripheral
15-C-0078Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAsNo longer recruiting/follow-up only18-65 YearsNCI Peripheral
15-AR-0060The Role of PPAR-gamma Agonists in immunomodulation and Vascular Prevention in SLE (PPAR-SLE)Completed Study; data analyses ongoing18-99 YearsNIAMSPeripheral
14-I-0020Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine ModelsParticipants currently recruited/enrolled18-65 YearsNIAIDPeripheral
14-HG-0048Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)Participants currently recruited/enrolled21-125 YearsNHGRIPeripheral
14-H-0077Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals with Higher Risk of Transplant FailureParticipants currently recruited/enrolled4-125 YearsNHLBIPeripheral
14-C-0163Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic AnalysisCompleted Study; data analyses ongoing10-125 YearsNCI Peripheral
14-C-0059A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults with GD2+ Solid TumorsCompleted Study; data analyses ongoing1-35 YearsNCI Osteosarcoma
13-C-0132Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC SyndromeParticipants currently recruited/enrolled8-70 YearsNCI Peripheral
11-I-0007Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age with X-Linked Severe Combined ImmunodeficiencyClinical hold/Recruitment or enrollment suspended2-40 YearsNIAIDPeripheral
10-C-0201Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 DeficiencyParticipants currently recruited/enrolled18-40 YearsNCI Peripheral
09-H-0225Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-ThalassemiaNo longer recruiting/follow-up only2-125 YearsNHLBIPeripheral
08-N-0044A Prospective Natural History Study of Patients with Neurofibromatosis Type 2 (NF2).Participants currently recruited/enrolled8-75 YearsNINDSPeripheral
08-H-0046Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated with Severe Neutropenia Refractory to Immunosuppressive TherapyCompleted Study; data analyses ongoing4-75 YearsNHLBIPeripheral
08-C-0130A Phase II Trial of Peginterferon alfa-2b (PEG-Intron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform NeurofibromasCompleted Study; data analyses ongoing0-21 YearsNCI Peripheral
08-C-0079Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults with Neurofibromatosis Type 1No longer recruiting/follow-up only0-125 YearsNCI Peripheral
07-N-0122Modulation of Motor Function by Stimulation of the Central and Peripheral Nervous SystemCompleted Study; data analyses ongoing18-125 YearsNINDSPeripheral
05-H-0130Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell TransplantsParticipants currently recruited/enrolled7-80 YearsNHLBIPeripheral
03-H-0170Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Severe Congenital Anemias Including Sickle Cell Disease (SCD) and Beta-ThalassemiaParticipants currently recruited/enrolled2-125 YearsNHLBIPeripheral
02-I-0286Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic SyndromeParticipants currently recruited/enrolled2-125 YearsNIAIDPeripheral
02-H-0250A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1HCompleted Study; data analyses ongoing18-125 YearsNHLBIPeripheral
02-C-0064Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation TherapyEnrolling by Invitation18-125 YearsNCI Peripheral
00-N-0043Clinical and Molecular Manifestations of Inherited Neurological DisordersParticipants currently recruited/enrolled2-125 YearsNINDSPeripheral
99-H-0050Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic DiseasesCompleted Study; data analyses ongoing2-80 YearsNHLBIPeripheral
96-H-0049Use of Granulocyte Colony Stimulating Factor (G-CSF) Mobilized Leukapheresis Collections from Healthy Volunteers to Develop Improved Methods of Stem Cell and Lymphocyte Selection for Allogeneic TransplantationParticipants currently recruited/enrolled18-60 YearsNHLBIPeripheral
94-I-0079Eosinophil Activation and Function in Parasitic Infections and Other Conditions with Increased Tissue or Peripheral Blood Eosinophilia in HumansParticipants currently recruited/enrolled1-100 YearsNIAIDPeripheral
94-I-0073Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and GranulocytesParticipants currently recruited/enrolled18-70 YearsNIAIDPeripheral
93-I-0063Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T CellsParticipants currently recruited/enrolled0-99 YearsNIAIDPeripheral
92-I-0125A Study of Viral Burden in Peripheral Blood Versus Lymphoid and Bone Marrow Tissue in HIV-Infected IndividualsParticipants currently recruited/enrolled18-125 YearsNIAIDPeripheral
91-I-0140Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in HIV-Infected and HIV-Uninfected VolunteersParticipants currently recruited/enrolled18-125 YearsNIAIDPeripheral
10 Center Drive,Bethesda, MD 20892 | Directions
Privacy Statement | Accessibility | Plain Language | FOIA | Disclaimer
Clinical Center | National Institutes of Health | HHS Vulnerability Disclosure | U.S. Department of Health and Human Services | USA.gov
NIH…Turning Discovery Into Health®